Co-Authors
This is a "connection" page, showing publications co-authored by Mitchell Posner and Mark Talamonti.
Connection Strength
0.541
-
Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Ann Surg Oncol. 2016 06; 23(6):1956-62.
Score: 0.129
-
Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015 Jul; 22(7):2209-17.
Score: 0.120
-
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
Score: 0.055
-
A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol. 2022 Oct 14; 6(1):72.
Score: 0.052
-
Virtual Surgical Fellowship Recruitment During COVID-19 and Its Implications for Resident/Fellow Recruitment in the Future. Ann Surg Oncol. 2020 Dec; 27(Suppl 3):911-915.
Score: 0.044
-
Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 11 13; 9(1):4827.
Score: 0.039
-
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793.
Score: 0.038
-
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
Score: 0.037
-
Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol. 2014 May; 21(5):1520-9.
Score: 0.028